In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies in most solid neoplasms, which necessitates the exploration of new immunotherapeutic modalities. The failure o...
Populations of T cells that are specific for tumour-associated antigens can be expanded to generate large numbers of cells and transferred into tumour-bearing hosts, a process known as adoptive cell transfer (ACT)-based immunotherapy. T cells can be genetically engineered to express αβ T cell...
As an important part of the immune system, T lymphocytes exhibit undoubtedly an important role in targeting and eradicating cancer. However, despite these characteristics, their natural antitumor response may be insufficient. Numerous clinical trials in
Adoptive immunotherapy and dendritic cell immunotherapy are forms of cellular therapy, where ex-vivo processed cells are introduced into the body. Adoptive immunotherapy uses immune effector cells (e.g., T cells), whereas dendritic cell immunotherapy uses antigen-presenting cells. Pre-clinical studies ...
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment Xianjun Li Tianjun Chen Tongsen Zheng Experimental Hematology & Oncology(2024) CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond ...
Like CIK cells, another alternatively novel immunotherapy chimeric antigen receptor T-cell (CAR-T) also showed great promise for NSCLC. However, unlike hematologic malignancies, the clinical application of CAR-T cells has remained limited success due to on-target/off-tumor as well as neurological ...
Chimeric antigen receptor (CAR) T-cell therapy is an innovative form of immunotherapy wherein autologous T cells are genetically modified to express chimeric receptors encoding an antigen-specific single-chain variable fragment and various costimulatory molecules. Upon administration, these modified T cells...
The fate of CD8+T cells is highly correlated with immunotherapy and prognosis [48,49]. CRISPR–Cas9 can edit the differentiation pathways, metabolic pathways, and the expression of inhibitory signaling molecules in CD8+T cells without compromising their in vivo function [50]. Metabolic pathways con...
Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both genetic and non-genetic approaches, facilitate the optimization of ad...
Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism Biol Blood Marrow Transplant, 15 (4) (2009), pp. 421-431 View PDFView articleView in ScopusGoogle Scholar 4 U Gergis, EM Frenet, T Shore, et al. Adoptive immunotherapy with cord blood...